公司概述
Kymera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by utilizing the body's intrinsic natural protein degradation system. The company functions within the broader Healthcare sector, specifically positioning itself in the specialized Biotechnology industry where innovation in protein degradation mechanisms defines its strategic focus. In terms of scale, the company holds a market capitalization of $7.13B, reports trailing twelve-month revenue of $39.21M, and employs a workforce of 238 individuals. The market cap figure of $7.13B, when juxtaposed against the relatively modest annual revenue of $39.21M, indicates that the company's valuation is driven primarily by its pipeline potential and future clinical outcomes rather than current operational cash flows, reflecting the typical capital-intensive nature of early-stage biotechnology firms.
财务健康
Kymera Therapeutics generated total revenue of $39.21M over the trailing twelve months, yet reported a net income loss of $-311,351,008 and an EBITDA of $-338,831,008. The substantial gap between the $39.21M in revenue and the $-311,351,008 in net income reveals a cost structure heavily dominated by research and development expenditures typical of clinical-stage operations, where significant capital is required to advance therapeutic candidates before commercialization. The company's free cash flow stands at $-136,041,248, indicating a consumption of cash reserves that necessitates ongoing capital raising or asset monetization to maintain financial flexibility in the absence of positive operating cash generation. Analyzing the margins, the gross margin is recorded at 0.0%, the operating margin at -3411.0%, and the profit margin at 0.0%, figures that collectively highlight the extreme cost leverage and lack of profitability inherent in the pre-revenue phase of the company's lifecycle. Regarding balance sheet liquidity, total cash holdings of $848.28M significantly exceed total debt obligations of $82.25M, resulting in a debt-to-equity ratio of 5.21 which suggests a leveraged capital structure driven by equity dilution rather than traditional debt financing. Despite the high debt-to-equity ratio, the current ratio of 10.47 indicates an exceptionally strong short-term liquidity position, suggesting the company possesses ample current assets to cover immediate liabilities without distress. Furthermore, the return on equity is -25.8% and the return on assets is -15.9%, metrics that reveal management is currently unable to generate positive returns on capital deployed, a common characteristic for biotechnology firms investing heavily in pipeline development prior to product approval.
估值评估
The valuation metrics for Kymera Therapeutics present a complex picture, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is -21.79. The discrepancy between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in future earnings expectations that have not yet materialized in historical financial results, rendering traditional earnings-based valuation multiples inapplicable for standard comparison. The price-to-book ratio stands at 4.50, indicating that the market assigns a significant premium to the company's intangible assets and pipeline value relative to its tangible book equity. Additionally, the price-to-sales ratio is 181.87 and the EV/EBITDA is -18.79, suggesting that alternative valuation metrics are being used to assess value based on revenue generation and enterprise value relative to earnings power, rather than profitability. In terms of price volatility range, the stock has a 52-week high of $103.00 and a 52-week low of $19.45, meaning the current price sits at a level that reflects significant downside from the yearly peak but retains substantial upside potential relative to the recent low. The beta value of 2.29 indicates that the stock's price volatility is more than double that of the broader market, implying that the company's share price is highly sensitive to market fluctuations and sector-specific risks.
Growth & Income
Kymera Therapeutics reported a revenue growth rate of -61.2% year-over-year, while earnings growth is listed as N/A due to the company's continued losses. The negative revenue growth combined with N/A earnings growth implies that the company is currently in a phase where top-line expansion is being constrained by operational scaling or pipeline development cycles, rather than experiencing the rapid scaling often seen in late-stage commercialization. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings are theoretically reinvested into growth initiatives rather than distributed to shareholders, although the net loss limits the actual funds available for reinvestment to cash reserves. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, reflecting the capital-intensive strategy of funding clinical trials and research through retained earnings and external financing rather than shareholder returns.